Armata Pharmaceuticals, Inc.

ARMP

$5.66

+2.54%

2026-09-04 12:09:18 EDT+$0.14

Healthcare

Biotechnology

AMEX

Active Trading

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is ...

Price Action of ARMP

$5.66

+2.54%+$0.14

High—

Low—

52W High-62.2%

Rel. vol—

Interval

Range1.5h

Volume—SMA5SMA10

—

Key Metrics of ARMP

Snapshot

Latest / TTM · 6 periods

Market Cap

$210.45M

ROCE

25.4%

EV / EBITDA

-2.92x

+71.4% YoY

FCF Yield

-12.7%

-1.2% YoY

Cash Conversion Cycle

-135.4d

Current Ratio

0.11

Quick take

Financial Highlights of ARMP

Profitability trend

Latest / TTM · 6 periods

Gross Margin

68.2%

Net Margin

-5825.3%

P/E Ratio

-1.04x

n/a

Debt / Equity

-1.36

n/a

Current Ratio

0.11

Dividend Yield

0.0%

Understanding

Calendar of ARMP

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.56 · Revenue $450000.00 · 1 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.40 · Revenue $515000.00 · 1 analysts

Financial Statements of ARMP

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
The total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).

Insider Transactions of ARMP

Acquisitions (A)

Since Mar 9, 2026

Disposals (D)

Since Mar 9, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Leadership Team of ARMP

5 executives

Name	Title	Compensation	Gender	Year Born	Status
Deborah L. Birx	Chief Executive Officer & Director	USD 851,908	—	1957	Active
Pierre Kyme	Chief Business Officer	USD 625,750

Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update

LOS ANGELES, Aug. 12, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended June 30, 2026, and provided a corporate update. "We continue to finalize activities required to initiate a pivotal Phase 3 superiority study of AP-SA02 in complicated S.

Historical Employee Count of ARMP

Current

Change

+1.67%

Minimum

Maximum

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-4.80 vs -1.64	-193.6%	-0.27 vs -0.45	+39.3%
Revenue Surprise	$4.9M vs $4.5M	+7.8%	$2.5M vs $400000	+527.5%

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	61	10-K	Mar 25, 2026	View
Dec 31, 2024	60	10-K	Mar 21, 2025	View
Dec 31, 2023	66	10-K	Mar 21, 2024	View
Dec 31, 2022	72	10-K	Mar 16, 2023	View
Dec 31, 2021	69	10-K	Mar 17, 2022	View

Date	Executive	Title	Security	Side	Shares	Price
Jul 10, 2026	Birx Deborah	director, officer: Chief Executive Officer	Common Stock	D	14,041	$4.26
Apr 24, 2026	Gilmer Daniel B.	director	Stock Options (Right to Buy)	A	51,280	$12.92
Apr 24, 2026	Gilmer Daniel B.	director:	—	—	0	—
Mar 14, 2026	Kyme Pierre	officer: Chief Business Officer	Common Stock	D	1,030	$10.54
Mar 14, 2026	Birx Deborah	director, officer: Chief Executive Officer	Common Stock	D	4,919	$10.54

Armata Pharmaceuticals, Inc.

Upcoming

Q3 FY2026 · Estimated results

Q4 FY2026 · Estimated results

Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update

Related stocksBiotechnology

Upcoming

Q3 FY2026 · Estimated results

Q4 FY2026 · Estimated results

Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update

Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?

Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02

Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia

Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02

FY2026 · Estimated annual results

FY2027 · Estimated annual results

Recent history

Q2 FY2026 · Results reported

Q1 FY2026 · Results reported

FY2025 · Annual results

Q3 FY2025 · Results reported

Q2 FY2025 · Results reported

Q1 FY2025 · Results reported

Recent Filings